Secukinumab in Ankylosing Spondylitis Patients: A Cost-per-Responder Analysis from the Indonesian Health System Perspective

OBJECTIVE: There are no publications that have demonstrated economic value for ankylosing spondylitis (AS) treatments in Indonesia. Cost per responder (CPR) is a lean method of economic evaluation. We estimated CPR from Indonesia’s health system perspective following AS treatment with secukinumab re...

Descripción completa

Detalles Bibliográficos
Autores principales: Wahono, Cesarius Singgih, Hamijoyo, Laniyati, Hendrawan, Yuriawati, Rakinaturia, Liyana, Mittal, Neha, Khanna, Prabal, Jain, Minal, Isbagio, Harry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333162/
https://www.ncbi.nlm.nih.gov/pubmed/37209274
http://dx.doi.org/10.1007/s41669-023-00401-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333162/
https://www.ncbi.nlm.nih.gov/pubmed/37209274
http://dx.doi.org/10.1007/s41669-023-00401-6

Ejemplares similares